MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Heron Therapeutics Company Profile (NASDAQ:HRTX)

Consensus Ratings for Heron Therapeutics (NASDAQ:HRTX) (?)
Ratings Breakdown: 9 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $51.44 (185.80% upside)

Analysts' Ratings History for Heron Therapeutics (NASDAQ:HRTX)
Show:
DateFirmActionRatingPrice TargetActions
6/27/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2016Cantor FitzgeraldReiterated RatingBuy$41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Brean CapitalReiterated RatingBuy$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016Noble FinancialReiterated RatingBuy$51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Cowen and CompanyReiterated RatingBuy$47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/15/2016Lake Street CapitalReiterated RatingBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2015JMP SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2015Bank of AmericaBoost Price TargetBuy$54.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Heron Therapeutics (NASDAQ:HRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/5/2016        
5/5/2016Q1($0.92)($0.92)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2016Q4($0.64)($0.87)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2015Q3($0.67)($0.63)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2015($0.65)($0.74)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015Q115($0.68)($0.70)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2015($0.79)($0.71)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014($0.69)($0.66)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2014($0.62)($0.78)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.67)($0.74)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014($0.53)($0.75)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Heron Therapeutics (NASDAQ:HRTX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.21)($0.90)($1.06)
Q2 20163($0.98)($0.92)($0.95)
Q3 20163($0.87)($0.83)($0.85)
Q4 20163($0.77)($0.75)($0.76)
(Data provided by Zacks Investment Research)
Dividend History for Heron Therapeutics (NASDAQ:HRTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Heron Therapeutics (NASDAQ:HRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/21/2016Robert RosenPresidentSell200,000$23.23$4,646,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Kevin C TangDirectorBuy121,212$24.75$2,999,997.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2015Kevin C TangDirectorBuy150,000$20.62$3,093,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Kimberly ManhardDirectorSell2,708$21.17$57,328.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2014Barry D QuartCEOBuy10,000$11.75$117,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2014Kevin C TangDirectorBuy510,638$11.75$5,999,996.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Barry D QuartCEOBuy1,000,000$0.40$400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Heron Therapeutics (NASDAQ:HRTX)
DateHeadline
06/30/16 07:21 AMHeron Therapeutics Inc (HRTX) Current Analyst Ratings - Fiscal Standard
06/30/16 07:21 AMHeron Therapeutics Inc (HRTX) Updated Price Targets - FTSE News
06/27/16 08:50 AMHeron Therapeutics Inc (HRTX) Broker Price Targets For The Coming Week - Fiscal Standard
06/24/16 07:06 AMBroadfin Capital LLC Decreased Stake in Heron Therapeutics INC (NASDAQ:HRTX) by $13.80 Million as Shares ... - Press Telegraph
06/22/16 04:35 PMCompany Update (NASDAQ:HRTX): Heron Therapeutics Inc Announces Appointment of Christian Waage to Board of ... - Smarter Analyst
06/22/16 03:16 PMHERON THERAPEUTICS, INC. /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to -
06/22/16 07:29 AMHeron Therapeutics Announces Appointment of Christian Waage to Board of Directors - [at noodls] - REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 22, 2016-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that ...
06/21/16 04:12 PMStrong Buy Calls Count For Heron Therapeutics, Inc. (NASDAQ:HRTX) At 9 - Investor Newswire
06/20/16 10:42 AMHeron Therapeutics, Inc. Stock Momentum Hits Weakness - CML News
06/16/16 04:29 PMRecently Issued Stock Ratings For Heron Therapeutics Inc (HRTX) - Fiscal Standard
06/14/16 04:21 PMTrend Of Rating Given To Heron Therapeutics, Inc. (NASDAQ:HRTX) - Investor Newswire
06/07/16 04:40 PMHeron Therapeutics Inc (HRTX) Jumps 5.35% on June 06 - Equities.com
06/05/16 07:10 AMAre Analysts Bearish Heron Therapeutics Inc (NASDAQ:HRTX) After Last Week? - HNN
06/04/16 07:12 AMHealthcare Trading Stocks: Heron Therapeutics, Inc. (NASDAQ:HRTX) , Apricus Biosciences, Inc (NASDAQ:APRI) - Is stories
06/02/16 07:14 AMTarget Price and Stock Performance Rundown for Heron Therapeutics, Inc. (NASDAQ:HRTX) - HNN - Target Price and Stock Performance Rundown for Heron Therapeutics, Inc. (NASDAQ:HRTX)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Heron Therapeutics, Inc. (NASDAQ ...and more »
06/02/16 07:14 AMBroker Watchlist: Heron Therapeutics Inc (HRTX) - Share Trading News - Broker Watchlist: Heron Therapeutics Inc (HRTX)Share Trading News09/23/2015 – Heron Therapeutics Inc had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 58 price target on the stock. The share price of Heron Therapeutics Inc (HRTX) was down -3.18% during the last trading session, with a day ...and more »
06/01/16 04:02 PMHeron Therapeutics, Inc. :HRTX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/29/16 10:26 PMHeron Therapeutics Inc (HRTX) Rating Reiterated by Cantor Fitzgerald - Let Me Know About This - Heron Therapeutics Inc (HRTX) Rating Reiterated by Cantor FitzgeraldLet Me Know About ThisHeron Therapeutics Inc (NASDAQ:HRTX)'s stock had its “buy” rating reissued by equities researchers at Cantor Fitzgerald in a report released on Sunday. Several other brokerages have also recently issued reports on HRTX. Cowen and Company restated a ...Heron Therapeutics Incorporated (NASDAQ:HRTX) Sellers Increased By 2.62% Their ShortsHNNall 18 news articles »
05/28/16 10:32 PMHeron Therapeutics Inc (HRTX) Drops 6.66% on May 26 - Heron Therapeutics Inc (HRTX) was one of the Russell 2000's biggest losers for Thursday May 26 as the stock slid 6.66% to $19.20, a loss of $-1.37 per share. Starting at an opening price of $20.28 a share, the stock traded between $18.85 and $20.39 over ...
05/27/16 05:45 PMHeron Therapeutics Inc (HRTX) Drops 6.66% on May 26 - Equities.com - Heron Therapeutics Inc (HRTX) Drops 6.66% on May 26Equities.comHeron Therapeutics Inc (HRTX) was one of the Russell 2000's biggest losers for Thursday May 26 as the stock slid 6.66% to $19.20, a loss of $-1.37 per share. Starting at an opening price of $20.28 a share, the stock traded between $18.85 and $20.39 ...and more »
05/27/16 08:39 AMEarnings Review and Stock Rundown for Heron Therapeutics, Inc. (NASDAQ:HRTX) - Wall Street Hints and News - Earnings Review and Stock Rundown for Heron Therapeutics, Inc. (NASDAQ:HRTX)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Heron Therapeutics, Inc. (NASDAQ:HRTX) to ...and more »
05/26/16 08:47 AMBroadfin Capital LLC Decreased Stake in Heron Therapeutics INC (NASDAQ:HRTX) by $13.80 Million as Shares ... - CCH Daily News - Broadfin Capital LLC Decreased Stake in Heron Therapeutics INC (NASDAQ:HRTX) by $13.80 Million as Shares ...CCH Daily NewsKevin Kotler decreased its stake in Heron Therapeutics Inc (NASDAQ:HRTX) by 34.34% based on its latest 2016Q1 regulatory filing with the SEC. Broadfin Capital Llc sold 766,526 shares as the company's stock declined 24.22% while stock markets rallied.and more »
05/26/16 08:47 AMPreview of Stock's Movement: Heron Therapeutics, Inc. (NASDAQ:HRTX) , ConforMIS, Inc. (NASDAQ:CFMS) , - Street Updates - Preview of Stock's Movement: Heron Therapeutics, Inc. (NASDAQ:HRTX) , ConforMIS, Inc. (NASDAQ:CFMS) ,Street UpdatesOn 5/25/2016, shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) rose +0.19% in trading session and finally closed at $20.57. The company most recent volume stood at 407.36 thousand shares as compared to its average volume of 653.57 thousand ...
05/23/16 10:27 AMNew Broker Ratings For Heron Therapeutics Inc (HRTX) - FTSE News - New Broker Ratings For Heron Therapeutics Inc (HRTX)FTSE News09/23/2015 – Heron Therapeutics Inc had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 58 price target on the stock. The share price of Heron Therapeutics Inc (HRTX) was up +9.20% during the last trading session, with a day ...Broker Outlook For The Week Ahead Heron Therapeutics Inc (HRTX)Share Trading NewsHealthcare Weekly Gainers: Novavax, Inc. (NASDAQ:NVAX), Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ...KC Registerall 3 news articles »
05/20/16 05:27 PMHeron Therapeutics Inc (HRTX) Jumps 9.2% on May 20 - Equities.com - Heron Therapeutics Inc (HRTX) Jumps 9.2% on May 20Equities.comHeron Therapeutics Inc (HRTX) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 9.2% to $19.47, representing a gain of $1.64 per share. Some 696,766 shares traded hands on 6,036 trades, compared with an ...and more »
05/19/16 10:40 PMRevenue Update on Heron Therapeutics Inc(NASDAQ:HRTX) - Trade Calls - Revenue Update on Heron Therapeutics Inc(NASDAQ:HRTX)Trade CallsHeron Therapeutics Inc(NASDAQ:HRTX) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 5, 2016. Company reported revenue of $0.00. Analysts estimated a revenue of $460.00K. Earnings per ...Heron Therapeutics Inc (HRTX) Updated Analyst CoverageRisers & Fallersall 3 news articles »
05/19/16 08:48 AMStocks within Traders Radar: Insulet Corporation (NASDAQ:PODD) , Heron Therapeutics, Inc. (NASDAQ:HRTX) - Street Updates - Stocks within Traders Radar: Insulet Corporation (NASDAQ:PODD) , Heron Therapeutics, Inc. (NASDAQ:HRTX)Street UpdatesAnalyst's consensus target price is measured at $37.45 for twelve month. Heron Therapeutics, Inc. (NASDAQ:HRTX) moved in red zone with decline of -0.07 points or -0.40% to $17.58.Total 427.41 thousand shares were exchanged in last trading session as ...and more »
05/18/16 11:22 AMHeron and the Never-Ending FDA Drug Review -
05/17/16 10:29 PMCantor Fitzgerald Initiates Coverage on Heron Therapeutics Inc to Buy - Trade Calls - Cantor Fitzgerald Initiates Coverage on Heron Therapeutics Inc to BuyTrade CallsCantor Fitzgerald Initiates Coverage on Heron Therapeutics Inc(NASDAQ:HRTX). The shares have been rated Buy. The rating by Cantor Fitzgerald was issued on May 2, 2016. Heron Therapeutics Inc (HRTX) made into the market gainers list on Mondays ...
05/17/16 05:21 PMHeron Therapeutics Inc (HRTX) Jumps 5.57% on May 16 - Equities.com - Heron Therapeutics Inc (HRTX) Jumps 5.57% on May 16Equities.comHeron Therapeutics Inc (HRTX) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 5.57% to $17.24, representing a gain of $0.91 per share. Some 517,018 shares traded hands on 4,383 trades, compared with an ...and more »
05/16/16 02:09 PMHere's Why Trevena Stock Dropped 18% Today -
05/16/16 10:27 AMAfter Last Week What Do Analysts Think Of Heron Therapeutics Inc (HRTX) - Share Trading News - After Last Week What Do Analysts Think Of Heron Therapeutics Inc (HRTX)Share Trading News09/23/2015 – Heron Therapeutics Inc had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 58 price target on the stock. The share price of Heron Therapeutics Inc (HRTX) was down -0.43% during the last trading session, with a day ...Heron Therapeutics Incorporated (NASDAQ:HRTX) Shorted Shares Decreased By 1.4%Franklin Independentall 4 news articles »
05/12/16 05:51 PMHeron Therapeutics, Inc. (NASDAQ:HRTX) Latest Impact Score At 0 - RealistInvestor.com - Heron Therapeutics, Inc. (NASDAQ:HRTX) Latest Impact Score At 0RealistInvestor.comHeron Therapeutics, Inc. (NASDAQ:HRTX) has a 0.31 daily sentiment score given by Alpha One after scanning articles on various online news platform. Alpha One performs algorithm based analysis to reach stock sentiment based on content published on ...
05/12/16 12:04 PMHERON THERAPEUTICS, INC. /DE/ Financials -
05/09/16 05:39 PMBig Movers: Heron Therapeutics, Inc. (NASDAQ:HRTX), Etsy, Inc. (NASDAQ:ETSY), Baylake Corp. (NASDAQ:BYLK ... - KC Register - Big Movers: Heron Therapeutics, Inc. (NASDAQ:HRTX), Etsy, Inc. (NASDAQ:ETSY), Baylake Corp. (NASDAQ:BYLK ...KC RegisterHeron Therapeutics, Inc. (NASDAQ:HRTX) reported first quarter 2016 financial results and highlighted recent corporate progress. As of March 31, 2016, Heron had approximately $100.4 million in cash, cash equivalents and short-term investments, compared ...and more »
05/09/16 05:39 PMEarnings Review: Heron Therapeutics Inc (NASDAQ:HRTX) - News Oracle - Earnings Review: Heron Therapeutics Inc (NASDAQ:HRTX)News OracleLast Trade: The Company fell -9.75% and finished at $16.84. The daily volume was measured at 1.34 million shares. The 52-week high of the share price is $42.24 and the 52-week low is $11.54. The company has a market cap of $557.11 million. Its latest ...and more »
05/08/16 05:55 PMHeron Therapeutics Inc (HRTX) Broker Price Targets For The Coming Week - Share Trading News - Heron Therapeutics Inc (HRTX) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Heron Therapeutics Inc (HRTX). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...and more »
05/07/16 05:08 PMAnalyst Rating Trends to Observe: Heron Therapeutics, Inc. (NASDAQ:HRTX) , Ovascience Inc. (NASDAQ:OVAS) - Street Updates - Analyst Rating Trends to Observe: Heron Therapeutics, Inc. (NASDAQ:HRTX) , Ovascience Inc. (NASDAQ:OVAS)Street UpdatesHeron Therapeutics, Inc. (NASDAQ:HRTX) decreased -9.75% or -1.82 points. The company traded volume of 1.34 million shares more than average volume of 685.07 thousand shares. Its EPS ratio for the past year is recorded at -2.87. The stock's last trade ...
05/06/16 10:52 PMEarnings Outlook on Heron Therapeutics, Inc. (NASDAQ:HRTX) - B.O.D.Y Confidential - Earnings Outlook on Heron Therapeutics, Inc. (NASDAQ:HRTX)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Heron Therapeutics, Inc. (NASDAQ:HRTX)'s next earnings release which is expected to be posted on or around 2016-08-05. Sell-side research firms on Wall Street are expecting that the company will post EPS of ...and more »
05/05/16 11:13 PMHeron Therapeutics, Inc. (NASDAQ:HRTX) Boasts An Average Rating Of 4 - RealistInvestor.com - Heron Therapeutics, Inc. (NASDAQ:HRTX) Boasts An Average Rating Of 4RealistInvestor.comAlpha One applies algorithm-based analytics for assessing a stock sentiment as per the published released on web channels. In this evaluation process, the group accesses the most relevant news platforms on a daily basis. Heron Therapeutics, Inc.and more »
05/05/16 11:13 PMBiotech Movers and Shakers:Heron Therapeutics Inc (NASDAQ:HRTX) and AMAG Pharmaceuticals, Inc. (NASDAQ ... - Market Exclusive - Market ExclusiveBiotech Movers and Shakers:Heron Therapeutics Inc (NASDAQ:HRTX) and AMAG Pharmaceuticals, Inc. (NASDAQ ...Market ExclusiveIn the development side of the space, it's the operational element of the reports that generally drive market capitalization, so here are two of the week's biggest movers so far – Heron Therapeutics Inc (NASDAQ:HRTX) and AMAG Pharmaceuticals, Inc.Broker Roundup For Heron Therapeutics Inc (HRTX)Share Trading NewsHeron Therapeutics Inc (NASDAQ:HRTX) Given Average Recommendation of "Buy" by BrokeragesWeb Breaking NewsHeron Therapeutics Inc's Trend Down, Especially After Today's Weak SessionB.O.D.Y ConfidentialBusiness Wire (press release)all 6 news articles »
05/05/16 11:13 PMHeron Therapeutics Inc (HRTX) Drops 5.76% on May 05 - Equities.com - Heron Therapeutics Inc (HRTX) Drops 5.76% on May 05Equities.comHeron Therapeutics Inc (HRTX) was one of the Russell 2000's biggest losers for Thursday May 05 as the stock slid 5.76% to $18.66, a loss of $-1.14 per share. Starting at an opening price of $19.78 a share, the stock traded between $18.21 and $20.53 ...and more »
05/05/16 06:04 PMHeron Therapeutics Inc (HRTX) Drops 5.76% on May 05 - Heron Therapeutics Inc (HRTX) was one of the Russell 2000's biggest losers for Thursday May 05 as the stock slid 5.76% to $18.66, a loss of $-1.14 per share. Starting at an opening price of $19.78 a share, the stock traded between $18.21 and $20.53 over ...
05/05/16 03:51 PMHeron Therapeutics reports 1Q loss -
05/05/16 03:20 PMHERON THERAPEUTICS, INC. /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
05/05/16 03:01 PMHeron Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Progress - [Business Wire] - Heron Therapeutics, Inc. , a biotechnology company focused on improving the lives of patients by developing best-in-class medicine that address major unmet medical needs, today reported first quarter 2016 financial results and highlighted recent corporate progress.
05/05/16 04:01 AMAverage Analyst Rating for Heron Therapeutics, Inc. (NASDAQ:HRTX) - B.O.D.Y Confidential - Average Analyst Rating for Heron Therapeutics, Inc. (NASDAQ:HRTX)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Heron Therapeutics, Inc. (NASDAQ:HRTX) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/03/16 06:47 AMCoverage initiated on Heron Therapeutics by Cantor Fitzgerald -
04/30/16 10:49 PMHow Analysts Feel About Heron Therapeutics Inc (NASDAQ:HRTX)? - B.O.D.Y Confidential - How Analysts Feel About Heron Therapeutics Inc (NASDAQ:HRTX)?B.O.D.Y ConfidentialOut of 8 analysts covering Heron Therapeutics (NASDAQ:HRTX), 8 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Heron Therapeutics has been the topic of 10 analyst reports since August 3, 2015 according to StockzIntelligence Inc.and more »
04/23/16 02:17 PMThis Was the Best Performing Healthcare ETF Last Week -
About Heron Therapeutics

Heron Therapeutics logoHeron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: HRTX
  • CUSIP:
Key Metrics:
  • Previous Close: $17.83
  • 50 Day Moving Average: $18.69
  • 200 Day Moving Average: $20.37
  • P/E Ratio: N/A
  • P/E Growth: -0.04
  • Market Cap: $N/A
  • Current Quarter EPS Consensus Estimate: $-3.56 EPS
Additional Links:
Heron Therapeutics (NASDAQ:HRTX) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha